Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
JS Heitmann, JS Walz, M Pflügler, J Kauer… - BMJ …, 2020 - search.proquest.com
Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
JS Heitmann, JS Walz, M Pflügler, J Kauer, RF Schlenk… - BMJ, 2020 - hero.epa.gov
INTRODUCTION: Prostate cancer is the second most common cancer in men worldwide.
When the disease becomes resistant to androgen-deprivation therapy, treatment options are …
When the disease becomes resistant to androgen-deprivation therapy, treatment options are …
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
JS Heitmann, JS Walz, M Pflügler, J Kauer… - BMJ …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
[引用][C] Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in …
JS Heitmann, JS Walz, M Pfluegler, J Kauer… - Bmj …, 2020 - ub01.uni-tuebingen.de
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and
preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant …
preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant …
[引用][C] Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in …
JS Heitmann, JS Walz, M Pfluegler… - Bmj …, 2020 - tobias-lib.ub.uni-tuebingen.de
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and
preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant …
preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant …
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
JS Heitmann, JS Walz, M Pflügler, J Kauer, RF Schlenk… - BMJ Open, 2020 - europepmc.org
Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
JS Heitmann, JS Walz, M Pflügler, J Kauer, RF Schlenk… - BMJ Open, 2020 - europepmc.org
Prostate cancer is the second most common cancer in men worldwide. When the disease
becomes resistant to androgen-deprivation therapy, treatment options are sparse. To …
becomes resistant to androgen-deprivation therapy, treatment options are sparse. To …